Jupiter Neurosciences (JUNS)

$2.85 +2.89% on the day Market cap $103M 52-week range $2.25 to $2.97 Prices as of Oct 11, 2026
Open the full deep dive Get an alert at your buy price

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Jupiter Neurosciences's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from JUNS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Profitability0
Financial health1

Key numbers

P/E (trailing)—
P/E (forward)—
Price / free cash flow—
EV / EBITDA—
Price / sales—
Price / book—
Revenue growth—
Operating margin—
Net margin—
Return on equity—
Dividend yield—
Debt / equity—

Results from SEC filings

Fiscal years, from Jupiter Neurosciences's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year202320242025
Revenue—$0$21,796
Net income-$5M-$2M-$9M
Free cash flow———
EPS (diluted)-$0.18-$0.08-$0.25
Operating margin——-40873.2%

Superinvestors who own JUNS

From each investor's latest 13F filing (what a 13F shows).

None of the superinvestors we track held JUNS in their latest 13F.

Insider buying

Open-market purchases by Jupiter Neurosciences's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of JUNS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when JUNS trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters
Open JUNS in Investingly

Questions

Are Jupiter Neurosciences insiders buying the stock?

No open-market insider purchases of JUNS in the last 12 months, according to SEC Form 4 filings.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.